Jco precision oncology.

Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ...DOI: 10.1200/PO.20.00250 JCO Precision Oncology no. 5 (2021) 204-214. Published online January 14, 2021. Published online January 14, 2021. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical OutcomeThe introduction of NGS assays has allowed the cancer genome to be systematically studied, providing oncologists with more comprehensive, precise, predictive, prognostic, and diagnostic information. 2 NGS-based gene panel tests have successfully identified driver mutations in lung cancers, 3,4 colorectal cancer, 5 and breast cancer, 3 which in turn has resulted in the development and use of ...OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with …Web

DOI: 10.1200/PO.22.00294 JCO Precision Oncology no. 7 (2023) e2200294. Published online January 12, 2023. PMID: 36634300. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States ...A fellow M.D. is a medical doctor who has been given a fellowship, which is a residency that teaches doctors a sub-specialty, such as internal medicine, movement disorders, gynecologic oncology and pediatric hematology, according to the Uni...The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...

DOI: 10.1200/PO.23.00176 JCO Precision Oncology no. 7 (2023) e2300176. Published online December 1, 2023. PMID: 38039430. Utility of Tumor Mutational Burden as a …npj Precision Oncology is a new open-access journal committed to publishing cutting edge scientific research in all aspects of precision oncology from basic science to translational applications ...Web

The introduction of NGS assays has allowed the cancer genome to be systematically studied, providing oncologists with more comprehensive, precise, predictive, prognostic, and diagnostic information. 2 NGS-based gene panel tests have successfully identified driver mutations in lung cancers, 3,4 colorectal cancer, 5 and breast cancer, 3 which in turn has resulted in the development and use of ...Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to provide a detailed characterization of a patient's neoplasm ...DOI: 10.1200/PO.22.00363 JCO Precision Oncology no. 7 (2023) e2200363. Published online May 24, 2023. PMID: 37224427. Exceptional Response to Dual Colony-Stimulating ...DOI: 10.1200/PO.21.00141 JCO Precision Oncology no. 5 (2021) 1270-1280. Published online August 11, 2021. Published online August 11, 2021. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types

DOI: 10.1200/PO.17.00075 JCO Precision Oncology - published online October 10, 2017

As such, scientific outlets in general, and JCO Precision Oncology in particular, owe an immense debt of gratitude to our volunteer peer reviewers. JCO PO strives to provide the highest quality peer review, so in recognition of Peer Review Week 2023 and its theme of Peer Review and The Future of Publishing, ...

Most patients are diagnosed with early-stage breast cancer (EBC), which is potentially curable with standard treatments. 3 Although (neo)adjuvant chemotherapies (NAC) reduce the risk of recurrence and death, approximately 30% of patients with EBC will experience recurrence in the first 10 years after surgery. 4 Recent studies have reported that circulating tumor DNA (ctDNA) detection in ...Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with …Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO PostJCO PO is a peerreviewed onlineonly articlebased journal publishing original research reports opinions and reviews that advance the science and practice of precision oncology and define genomics and other biomarkerdriven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...Most patients are diagnosed with early-stage breast cancer (EBC), which is potentially curable with standard treatments. 3 Although (neo)adjuvant chemotherapies (NAC) reduce the risk of recurrence and death, approximately 30% of patients with EBC will experience recurrence in the first 10 years after surgery. 4 Recent studies have reported that circulating tumor DNA (ctDNA) detection in ...

OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions. DOI: 10.1200/PO.23.00338 JCO Precision Oncology no. 7 (2023) e2300338. Published online December 1, 2023. Published online December 1, 2023. Homologous Recombination Deficiency Across Subtypes of …Oct 31, 2022 · PURPOSE To facilitate implementation of precision medicine in clinical management of cancer, the European Society of Medical Oncology proposed in 2018 a new scale to harmonize and standardize the reporting and interpretation of clinically relevant genomics data (ESMO Scale of Actionability of molecular Targets [ESCAT]). This study aims to characterize the clinical impact of matching targetable ... Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017 Feb 21, 2023 · PURPOSE To develop and validate a cross-ancestry integrated risk score (caIRS) that combines a cross-ancestry polygenic risk score (caPRS) with a clinical estimator for breast cancer (BC) risk. We hypothesized that the caIRS is a better predictor of BC risk than clinical risk factors across diverse ancestry groups. METHODS We used diverse retrospective cohort data with longitudinal follow-up ... Dec 11, 2019 · Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to implement precision oncology in Japan. The most promising ... DOI: 10.1200/PO.21.00524 JCO Precision Oncology no. 6 (2022) e2100524. Published online September 14, 2022. PMID: 36103643. Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial Rachel W. Miller, MD 1. x. Rachel W. Miller. Search for articles by this author ...

Aug 11, 2022 · Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy.

Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to …WebJun 7, 2023 · The introduction of NGS assays has allowed the cancer genome to be systematically studied, providing oncologists with more comprehensive, precise, predictive, prognostic, and diagnostic information. 2 NGS-based gene panel tests have successfully identified driver mutations in lung cancers, 3,4 colorectal cancer, 5 and breast cancer, 3 which in turn has resulted in the development and use of ... DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...In this prospective, case-control study, we assessed the performance of a blood-based multi-cancer detection test to detect cancer and predict the origin of the cancer signal in individuals with symptoms suspicious for cancer.This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe. David Cohn. Consulting or Advisory Role: …DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsThe increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor …DOI: 10.1200/PO.20.00321 JCO Precision Oncology no. 5 (2021) 510-524. Published online March 19, 2021. Published online March 19, 2021. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyWebDOI: 10.1200/PO.23.00092 JCO Precision Oncology no. 7 (2023) e2300092. Published online July 6, 2023. PMID: 37410975. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness ...

The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of …Web

Apr 22, 2021 · PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ...

By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ...JCO Precision Oncology 10.1200/PO.17.00071 (2017). Google Scholar. Yoshida, G.J. Applications of patient-derived tumor xenograft models and tumor organoids ...DOI: 10.1200/PO.20.00532 JCO Precision Oncology no. 5 (2021) 1241-1249. Published online August 5, 2021. Published online August 5, 2021. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic ProfilingWebDOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryPURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we …DOI: 10.1200/PO.21.00152 JCO Precision Oncology no. 5 (2021) 1639-1649. Published online October 22, 2021. Published online October 22, 2021. PARP Inhibition in Prostate Cancer With Homologous Recombination Repair AlterationsThis author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. Research Funding: Ambry Genetics ...DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: TP Therapeutics, Nuvalent, Inc. Honoraria: Natera.

JCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer. DOI: 10.1200/PO.18.00299 JCO Precision Oncology - published online April 25, 2019 PMID: 32914040 Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung CancerDOI: 10.1200/PO.22.00531 JCO Precision Oncology no. 7 (2023) e2200531. Published online May 4, 2023. PMID: 37141549. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis Lorenzo Gerratana, MD 1. x. Lorenzo Gerratana. Search for articles by this …Instagram:https://instagram. cheapest futures brokerfox stockscgpaxbest free business expense tracker JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not …23 Aug 2021 ... JCO Precision Oncology 2018 :2, 1-13 [Full Text · External Web Site Policy ]. Methods. Wiant K, Geisen E, Creel D, Willis G, Freedman A, de Moor ... nyse achrc.m.i Jan 27, 2022 · This author is an Associate Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Ciitizen Corporation, Clariifi, Guidance Genomics. Consulting or Advisory Role: Roche, Roche/Genentech. Speakers' Bureau: Genentech small cap tech stocks DOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post Sep 29, 2021 · PURPOSE With the introduction of precision medicine, treatment options for non–small-cell lung cancer have improved dramatically; however, underutilization, especially in disadvantaged patients, like those living in rural Appalachian regions, is associated with poorer survival. Molecular tumor boards (MTBs) represent a strategy to increase precision medicine use. UK HealthCare at the ...